Author: Joelle Selmer
Publisher:
ISBN:
Category :
Languages : fr
Pages : 119

Get Book Here

Book Description

Author:
Publisher:
ISBN:
Category :
Languages : fr
Pages :

Get Book Here

Book Description

Author: Mossialos, Elias
Publisher: McGraw-Hill Education (UK)
ISBN: 0335214657
Category : Education
Languages : en
Pages : 390

Get Book Here

Book Description
"This thoughtful and comprehensive book represents the best work I have seen on the current situation concerning medication policies in the EU. It is not just that this is a very up-to-date compendium of facts and data across a wide variety of domains that impact on pharmaceutical regulation. The book is also strong on analysis of those facts as well." Jerry Avorn, Harvard Medical School. "This book offers a comprehensive examination of approaches to manage pharmaceutical expenditures in Europe. It is a must-read for those who seek to understand and navigate the changing regulatory environment for medicines in the European Union." Bernie O'Brien, McMaster University, Canada. The rising cost of pharmaceutical expenditures in many European countries is of concern to governments required to make effective use of health care budgets. Taking a broad perspective that encompasses institutional, political and supranational aspects of pharmaceutical regulation, this book examines approaches used to manage pharmaceutical expenditure across Europe and what impact these strategies have had on efficiency, quality, equity and cost of pharmaceutical care.Regulating Pharmaceuticals in Europe is an important book for students of health policy, regulation and management, and for health managers and policy makers. The editors: Elias Mossialos is Brian Abel-Smith Professor of Health Policy at the London School of Economics and Political Science and a Research Director of the European Observatory on Health Systems and Policies. Monique Mrazek is a Health Economist (Europe and Central Asia region) for the World Bank and formerly a Research Officer in Health Economics for the European Observatory on Health Systems and Policies. Tom Walley is Professor of Clinical Pharmacology at the University of Liverpool and Director of the UK National Health Technology Assessment Programme. Contributors:Julia Abelson, Christa Altenstetter, Vittorio Bertele’, Christine Bond, Marcel L. Bouvy, Colin Bradley, Steve Chapman, Anna Dixon, Michael Drummond, Pierre Durieux, Edzard Ernst, Armin Fidler, Eric Fortess, Richard Frank, Silvio Garattini, Leigh Hancher, Ebba Holme Hansen, Steve Hudson, Kees de Jonchere, Panos Kanavos, Sjoerd Kooiker, Jean-Marc Leder, Graham Lewis, Donald W. Light, Alistair McGuire, Elias Mossialos, Monique Mrazek, Maria Pia Orru', Govin Permanand, Guenka Petrova, Munir Pirmohamed, Dennis Ross-Degnan, Frans Rutten, Steven Soummerai, David Taylor, Sarah Thomson, Tom Walley.

Author: Eric Mollard
Publisher:
ISBN:
Category :
Languages : fr
Pages : 254

Get Book Here

Book Description

Author:
Publisher: John Libbey Eurotext
ISBN: 9782742001231
Category : Drugs
Languages : fr
Pages : 144

Get Book Here

Book Description

Author: Christine Carci
Publisher:
ISBN:
Category :
Languages : fr
Pages : 228

Get Book Here

Book Description
Dans une première partie est exposée la situation actuelle de l'industrie pharmaceutique en Europe occidentale. Sont notamment évoqués le problème de la libre circulation des médicaments et de la reconnaissance mutuelle des A.M.M., la contribution de l'industrie pharmaceutique à l'amélioration de la Santé, la consommation et le coût de la santé dans les pays européens. La deuxième partie est consacrée à la recherche et à son évolution dans un proche avenir. L'auteur est amené à présenter les nouvelles sources de médicaments, en particulier les biotechnologies qui connaissent un développement important. Ces procédés nouveaux ainsi que ceux des voies classiques devraient permettre à l'industrie pharmaceutique européenne de faire face à la concurrence intrenationale à condition de disposer d'une protection juridique de l'invention pharmaceutique plus prolongée dans le temps.

Author:
Publisher:
ISBN:
Category :
Languages : fr
Pages : 163

Get Book Here

Book Description

Author: Claude Bardot
Publisher:
ISBN:
Category :
Languages : fr
Pages : 160

Get Book Here

Book Description

Author: Bengt Domeij
Publisher: BRILL
ISBN: 9004481478
Category : Law
Languages : en
Pages : 365

Get Book Here

Book Description
The pharmaceutical industry and patent legislation are inextricably linked. Pharmaceutical companies could not exist without some guarantee that they can recoup the cost of developing a new product. European patent law offers this opportunity, as it allows companies to exclude competition for a specific product for a fixed time scale. In Pharmaceutical Patents in Europe the current legal patent situation is examined by a detailed analysis of case law from the European Patent Office (EPO), the international body created with the signing of the European Patent Convention (EPC). Aspects of European patent law not primarily regulated in the EPC, for example Supplementary Protection Certificates and infringement matters, are examined in the setting provided by EC law and domestic laws of European states. This book is written for the reader who understands the main characteristics of patent law and is looking for a practitioner's text on the European pharmaceutical patent law scene. Moreover, the author's remarks can help all readers to look at the field with fresh eyes.

Author: Boris Hauray
Publisher: PRESSES DE SCIENCES PO
ISBN: 2724686616
Category : Business & Economics
Languages : fr
Pages : 354

Get Book Here

Book Description
Lancés à partir de 1960, les efforts pour construire des politiques pharmaceutiques communes se sont vite heurtés aux intérêts nationaux et aux écarts de pratiques et de normes entre pays. En 1993, la création d’une structure institutionnelle innovante, l’Agence européenne du médicament, est finalement décidée et s’impose rapidement comme le cœur du contrôle des médicaments en Europe. Ce livre analyse, dans une Europe devenue le cadre normatif central et l’horizon stratégique des acteurs, toutes les questions traditionnellement appliquées aux politiques du médicament : comment et pourquoi juge-t-on un médicament acceptable ? Quelle implication les industriels ont-ils dans les procédures de contrôle ? La protection de la santé publique est-elle correctement assurée ? Quelle place les experts ont-ils dans les processus de décision politique ? S’intéresser à la régulation des médicaments paraît d’autant plus pertinent que le secteur pharmaceutique et son contrôle par les pouvoirs publics traversent une crise grave depuis quelques années.